Versant Ventures related stories
All articles and analysis
Acclarent Raises $26 MillionAcclarent Inc., a Menlo Park, Calif.-based developer of surgical devices for treating ear, nose and throat ailments, has raised $26 million in fourth-round funding. Johnson & Johnson Development Corp. joined return backers New Enterprise Associates, Delphi Ventures, Versant Ventures and Meritech Capital Partners. Last month, Acclarent withdrew registration for an $86.25 million IPO, citing "unfavorable market conditions."
- PE Week Wire: Monday, January 12, 2009
Random Ramblings
- PE Week Wire: Monday, January 12, 2009
Random Ramblings
- Anaphore Raises $25 Million
Anaphore Inc., a developer of protein therapeutics to address cancer and immune-mediated diseases, has raised $25 million in Series A funding. The round includes an $8 million seed funding that closed last March, while the remainder closed in December. Apposite Capital was joined on the second tranche by seed backers 5am Ventures and Versant Ventures.
- Synosia Therapeutics Raises $29 Million
Synosia Therapeutics, a Swiss drug developer focused on psychiatry and neurology, has raised CHF 32 million ($29m) in Series B funding. Aravis Venture and Investor Growth Capital co-led the round, and was joined by Swiss Helvetia Fund and return backers Versant Ventures, Abingworth, Novo A/S and 5am Ventures.
- PE Week Wire: Wednesday, January 7, 2009
Random Ramblings
- PE Week Wire: Wednesday, January 7, 2009
Random Ramblings
- PE Week Wire: Monday, December 8, 2008
Random Ramblings
- PE Week Wire: Monday, December 8, 2008
Random Ramblings